D Nakashima Selected Research

KW-2478

10/2017	A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
1/2016	Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

D Nakashima Research Topics

Disease

3	Neoplasms (Cancer) 01/2016 - 03/2006
2	Multiple Myeloma 10/2017 - 01/2016
2	Squamous Cell Carcinoma of Head and Neck 09/2007 - 03/2006
1	Rhinosinusitis 10/2023
1	Postoperative Pain 08/2021
1	Hemorrhage 08/2021
1	Pain (Aches) 08/2021
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2016
1	Toxic Optic Neuropathy 01/2016
1	Pseudolymphoma 12/2008
1	Carcinogenesis 09/2007

Drug/Important Bio-Agent (IBA)

2	KW-2478IBA 10/2017 - 01/2016
1	SteroidsIBA 10/2023
1	Acetaminophen (Paracetamol)FDA LinkGeneric 08/2021
1	Analgesics (Analgesic Drugs)IBA 08/2021
1	Bortezomib (Velcade)FDA Link 10/2017
1	Retinaldehyde (Retinal)IBA 01/2016
1	Amlodipine (Norvasc)FDA LinkGeneric 12/2008
1	glucose-regulated proteinsIBA 09/2007
1	Calcium-Binding ProteinsIBA 09/2007
1	Carrier Proteins (Binding Protein)IBA 09/2007
1	Histone Deacetylase InhibitorsIBA 06/2006
1	Hydroxamic Acids (Hydroxamic Acid)IBA 06/2006
1	anthranilamideIBA 06/2006
1	ZincIBA 06/2006
1	StathminIBA 03/2006
1	PhosphoproteinsIBA 03/2006
1	Biomarkers (Surrogate Marker)IBA 03/2006

Therapy/Procedure

1	Analgesia 08/2021
1	Perioperative Period 08/2021